Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 17/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.31 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.31 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501794 | 1.00 | JAK2 (0.62) | JAK2SMN1; SMN2KCNH2CSNK2A2CSNK2B | |
| SCHEMBL2879275 | 0.93 | JAK2 (0.67) | JAK2KCNH2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2879272 | 0.93 | JAK2 (0.67) | JAK2KCNH2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13225304 | 0.88 | JAK2 (0.68) | JAK2KCNH2 | |
| SCHEMBL3500133 | 0.85 | JAK2 (0.70) | JAK2KCNH2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL3500129 | 0.85 | JAK2 (0.70) | JAK2KCNH2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL2872878 | 0.85 | SMN1; SMN2 (0.41) | JAK2SMN1; SMN2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13225301 | 0.82 | JAK2 (0.55) | JAK2 | |
| SCHEMBL2875587 | 0.82 | JAK2 (0.76) | JAK2KCNH2CSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL11981830 | 0.81 | JAK2 (0.75) | JAK2KCNH2CSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | claimed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | claimed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | claimed |
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | JAK2 1/4885SMN1; SMN2 3716/4885KCNH2 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.